GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Retained Earnings

IDEAYA Biosciences (IDEAYA Biosciences) Retained Earnings : $-348.36 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. IDEAYA Biosciences's retained earnings for the quarter that ended in Dec. 2023 was $-348.36 Mil.

IDEAYA Biosciences's quarterly retained earnings declined from Jun. 2023 ($-286.97 Mil) to Sep. 2023 ($-314.41 Mil) and declined from Sep. 2023 ($-314.41 Mil) to Dec. 2023 ($-348.36 Mil).

IDEAYA Biosciences's annual retained earnings declined from Dec. 2021 ($-176.75 Mil) to Dec. 2022 ($-235.40 Mil) and declined from Dec. 2022 ($-235.40 Mil) to Dec. 2023 ($-348.36 Mil).


IDEAYA Biosciences Retained Earnings Historical Data

The historical data trend for IDEAYA Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Retained Earnings Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial -92.49 -126.99 -176.75 -235.40 -348.36

IDEAYA Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -235.40 -259.04 -286.97 -314.41 -348.36

IDEAYA Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


IDEAYA Biosciences  (NAS:IDYA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Traded in Other Exchanges
Address
7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Executives
Yujiro S Hata director, officer: President and CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz officer: See Remarks C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne officer: VP, General Counsel C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone officer: SVP, General Counsel C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre officer: SVP, Chief Medical Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White officer: SVP, Chief Scientific Officer C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon officer: SVP, Chief Scientific Officer C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner officer: SVP, Head of Biology C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab 10 percent owner, Former 10% holder C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner, Former 10% holder C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage 10 percent owner, Former 10% holder C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p. 10 percent owner, Former 10% holder 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

IDEAYA Biosciences (IDEAYA Biosciences) Headlines

From GuruFocus